Apr 18, 2024
|
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
|
|
Mar 20, 2024
|
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
|
|
Mar 8, 2024
|
CEO Update: Lumos Pharma Celebrates International Women’s Day
|
|
Mar 7, 2024
|
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
|
|
Feb 26, 2024
|
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
|
|
Feb 5, 2024
|
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
|
|
Jan 4, 2024
|
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
|
|
Nov 21, 2023
|
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
|
|
Nov 20, 2023
|
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
|
|
Nov 7, 2023
|
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
|
|